这是描述信息
Location:
Homepage
/
/
Fosun Pharma and Intuitive Surgical establish a joint venture in China to innovate, develop and sell lung cancer diagnosis and treatment tools

Fosun Pharma and Intuitive Surgical establish a joint venture in China to innovate, develop and sell lung cancer diagnosis and treatment tools

  • Categories:Trade info
  • Author:Fosun Pharma
  • Origin:
  • Time of issue:2016-09-30
  • Views:0

(Summary description)

Fosun Pharma and Intuitive Surgical establish a joint venture in China to innovate, develop and sell lung cancer diagnosis and treatment tools

(Summary description)

  • Categories:Trade info
  • Author:Fosun Pharma
  • Origin:
  • Time of issue:2016-09-30
  • Views:0
Information

On September 29, 2016, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (abbreviated as "Fosun Pharmaceutical", stock code: 600196.SH, 02196.HK) announced a partnership with Intuitive Surgical, Inc. (hereinafter Intuitive Surgical SARL, a wholly-owned subsidiary of "Intuitive Surgical" for short, has established a joint venture to develop, produce and sell products for the early diagnosis or treatment of lung cancer.

 

  Intuitive Surgical is a global leader in robot-assisted minimally invasive surgery. Its products have covered North America, South America, Europe, the Middle East, Australia and Asia; it is the world leader in the research and development, manufacturing and market of minimally invasive surgical robot technology. Fosun Pharma's business strategically covers the entire medical and health industry chain, and has demonstrated outstanding results in the distribution of surgical robots in China. The joint venture with Intuitive Surgical will be established in Shanghai. It will initially target one of the most common cancers in the world—lung cancer, and produce cost-effective products that are beneficial to its early diagnosis and treatment.

 “We are very much looking forward to deepening our partnership with Fosun Pharma to provide innovative medical solutions for China and the world." Intuitive Surgical President and CEO Dr. Gary Guthart said, "Intuitive Surgical is honored to be able to shoulder the responsibility This long-term commitment is vital to China. ”

 

  According to the business needs of the joint venture, the two companies will jointly inject 100 million US dollars. This move also marks the further important extension of the business relationship between Fosun Pharma and Intuitive Surgical. Since 2011, Fosun Pharma's subsidiary—Mutual Medical Co., Ltd. has become the distribution partner of Intuitive Surgical Da Vinci Surgical System in China.

 

  “We are very happy to further expand our partnership and lead the development of medical tools to help China’s rising lung cancer patients and even people around the world improve the quality and level of health. "Chen Qiyu, Chairman of Fosun Pharma, said, "This cooperation will promote the development of our medical device business, and it will also help Intuitive Surgical achieve brand and business concept integration, resource matching, complementary advantages, and continue to provide doctors with more Good diagnosis and treatment tools to improve medical results. ”

 

About Intuitive Surgical, Inc.

        IntuitiveSurgical, Inc. (Nasdaq:ISRG), headquartered in the United States, is a global leader in robot-assisted minimally invasive surgery. Da Vinci Surgical System is developed, produced and marketed by Intuitive Surgical.

Scan the QR code to read on your phone

Copyright hongqipharma.com All rights reserved     Powered by:300.cn Shenyang    辽icp备12005917号    (辽)-非经营性-2018-0012 

Add:Shenyang Hunnan New District envelope 6th Street    Tel:024-23786268-8012  Fax:024-23786263